Literature DB >> 23537397

Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.

Xavier Bresse1, Lieven Annemans, Emmanuelle Préaud, Karine Bloch, Gérard Duru, Aline Gauthier.   

Abstract

This study assesses the cost-effectiveness of vaccination against herpes zoster (HZ) and postherpetic neuralgia in France, using a published Markov model. The cost-effectiveness of vaccinating individuals aged from 65 years or between 70 and 79 years was evaluated over their lifetime, from a third-party payer perspective. French-specific data were combined with results from clinical studies and international quality-of-life-based (EuroQol five-dimension questionnaire) utilities from the literature. HZ vaccination was highly cost effective in both populations. Incremental cost-effective ratios were estimated between €9513 and 12,304 per quality-adjusted life year gained, corresponding to €2240-2651 per HZ case avoided and €3539-4395 per postherpetic neuralgia case avoided. In addition to epidemiological and clinical evidence, economic evidence also supports the implementation of HZ vaccination in France.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23537397     DOI： 10.1586/erp.13.19

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN： 1473-7167            Impact factor:   2.217


  13 in total

Review 1.  Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.

Authors:  Robert W Johnson; Marie-José Alvarez-Pasquin; Marc Bijl; Elisabetta Franco; Jacques Gaillat; João G Clara; Marc Labetoulle; Jean-Pierre Michel; Luigi Naldi; Luis S Sanmarti; Thomas Weinke
Journal:  Ther Adv Vaccines       Date:  2015-07

Review 2.  Cost-effectiveness of vaccination against herpes zoster.

Authors:  Pieter T de Boer; Jan C Wilschut; Maarten J Postma
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Clinical and economic impact of herpes zoster vaccination in elderly in Italy.

Authors:  Sara Boccalini; Cristiano Alicino; Domenico Martinelli; Angela Bechini; Emilia Tiscione; Barbara Pellizzari; Rosa Prato; Giancarlo Icardi; Stefania Iannazzo; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2016-12-07       Impact factor: 3.452

4.  Cost-effectiveness of a herpes zoster vaccination program among the French elderly people.

Authors:  Emmanuel Belchior; Daniel Lévy-Bruhl; Yann Le Strat; Magid Herida
Journal:  Hum Vaccin Immunother       Date:  2016-08-02       Impact factor: 3.452

Review 5.  Reducing the burden of Herpes Zoster in Italy.

Authors:  Giovanni Gabutti; Elisabetta Franco; Paolo Bonanni; Michele Conversano; Antonio Ferro; Marzia Lazzari; Stefania Maggi; Alessandro Rossi; Silvestro Scotti; Francesco Vitale; Antonio Volpi; Donato Greco
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

6.  Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review.

Authors:  Edward T Chiyaka; Van T Nghiem; Lu Zhang; Abhishek Deshpande; Patricia Dolan Mullen; Phuc Le
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.558

7.  Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.

Authors:  Emmanuelle Préaud; Mathieu Uhart; Katharina Böhm; Pamela Aidelsburger; Delphine Anger; Florence Bianic; Nathalie Largeron
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.

Authors:  Bernhard Ultsch; Felix Weidemann; Thomas Reinhold; Anette Siedler; Gérard Krause; Ole Wichmann
Journal:  BMC Health Serv Res       Date:  2013-09-26       Impact factor: 2.655

Review 9.  The humanistic, economic and societal burden of herpes zoster in Europe: a critical review.

Authors:  Adam Gater; Mathieu Uhart; Rachael McCool; Emmanuelle Préaud
Journal:  BMC Public Health       Date:  2015-02-27       Impact factor: 3.295

10.  ARIZONA study: is the risk of post-herpetic neuralgia and its burden increased in the most elderly patients?

Authors:  Martin Duracinsky; Marc Paccalin; Gaëtan Gavazzi; Sohéla El Kebir; Jacques Gaillat; Christophe Strady; Didier Bouhassira; Olivier Chassany
Journal:  BMC Infect Dis       Date:  2014-10-01       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.